Please login to the form below

Not currently logged in
Email:
Password:

Santaris

This page shows the latest Santaris news and features for those working in and with pharma, biotech and healthcare.

Roche boosts respiratory presence with InterMune purchase

Roche boosts respiratory presence with InterMune purchase

These include a $450m deal to acquire gene silencing specialist Santaris earlier this month, an offering of $1.7bn for cancer company Seragon in July and a $350m bargain for sequencing

Latest news

  • Chugai soars on Roche buyout rumours Chugai soars on Roche buyout rumours

    Roche has been making targeted acquisitions of late – offering $450m for gene silencing company Santaris earlier this month, $1.7bn for cancer company Seragon Pharmaceuticals in July and $350m for sequencing

  • Roche pays $450m for 'gene-silencing' firm Santaris Pharma Roche pays $450m for 'gene-silencing' firm Santaris Pharma

    Roche pays $450m for 'gene-silencing' firm Santaris Pharma. Deal marks major return to the RNAi field it exited four years ago. ... The deal is expected to close later this month, when Santaris' Danish operations will become the Roche Innovation Center

  • Shire extends rare genetic disease alliance

    Shire extends rare genetic disease alliance. Agrees option with Santaris to nominate additional discovery targets. ... Shire has expanded its rare genetic disease alliance with Danish biopharmaceutical company Santaris.

  • Shire appoints Soren Tulstrup to lead its MPS franchise

    Shire appoints Soren Tulstrup to lead its MPS franchise. He joins with experience from Santaris Pharma, Merck &Co, Sandoz and Abbott. ... Currently vice chairman of trade association EBE (European Biopharmaceutical Enterprises), Tulstrup was formerly

  • Sanofi and Regeneron start cholesterol antibody trials

    BMS-844421, a compound targeting PCSK9 in development at Bristol-Myers Squibb and Isis Pharmaceuticals, was discontinued last year, as was a similar antisense-based drug from Santaris called SPC5001.

More from news
Approximately 2 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Pharma deals during August 2014 Pharma deals during August 2014

    August also saw Roche's pRED group acquire Santaris Pharma for $450m - $250m upfront and $200m contingent on predetermined research milestones. ... Clearly it has not taken Roche long to be convinced of these claims given its $10m discovery alliance with

  • Deal Watch table for August 2014 Deal Watch table for August 2014

    587.5. Santaris/ Roche (pRED). Company acquisition. Locked Nucleic Acid (LNA) platform for RNA-targeting therapeutics.

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    Santaris/Roche. Discovery and development. Novel RNA targeted medicines using Santaris' locked nucleic acid drug platform.

  • Pharma deals during April 2013 Pharma deals during April 2013

    In addition to those already mentioned are: Ambrx / Astellas; Isis/ Roche; Ra/ Merck; Santaris/ Bristol-Myers Squibb (BMS). ... Santaris/ BMS. April also saw the announcement of yet another Santaris deal, this time with BMS to add to those already signed

  • Deal Watch table for April 2013 Deal Watch table for April 2013

    199. Velcera/ Perrigo Company. Acquisition. Pet health products. 160. Santaris Pharma/ BMS.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics